Nanomedicine: Nanotechnology, Biology and Medicine
Volume 6, Issue 3 , Pages 399-408 , June 2010

Selective removal of ovarian cancer cells from human ascites fluid using magnetic nanoparticles

  • Kenneth E. Scarberry, PhD

      Affiliations

    • School of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, GA, USA
    • ,
  • Erin B. Dickerson, PhD

      Affiliations

    • School of Biology, Georgia Institute of Technology, Atlanta, GA, USA
    • Ovarian Cancer Institute, Georgia Institute of Technology, Atlanta, GA, USA
    • ,
  • Z. John Zhang, PhD

      Affiliations

    • School of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, GA, USA
    • ,
  • Benedict B. Benigno, MD

      Affiliations

    • Ovarian Cancer Institute, Georgia Institute of Technology, Atlanta, GA, USA
    • ,
  • John F. McDonald, PhD

      Affiliations

    • School of Biology, Georgia Institute of Technology, Atlanta, GA, USA
    • Ovarian Cancer Institute, Georgia Institute of Technology, Atlanta, GA, USA
    • Corresponding Author InformationCorresponding author: School of Biology, Georgia Institute of Technology, 315 Ferst Street, Atlanta, Georgia 30332, USA.

Received 7 August 2009 ,Accepted 11 November 2009.

References 

  1. Flam F, Einhorn N, Sjovall K. Symptomatology of ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 1988;27:53–57
  2. Feldman GB, Knapp RC, Order SE, Hellman S. The role of lymphatic obstruction in the formation of ascites in a murine ovarian carcinoma. Cancer Res. 1972;32:1663–1666
  3. Hirabayashi K, Graham J. The genesis of ascites in ovarian cancer. Am J Obstet Gynecol. 1970;106:492–497
  4. Gabrilovich DI, Nadaf S, Corak J, Berzofsky JA, Carbone DP. Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice are effective antigen carriers in the therapy of established tumors. Cell Immunol. 1996;170:111–119
  5. Scholz C, Rampf E, Toth B, Brunnhuber R, Weissenbacher T, Friese K, et al. Ovarian cancer-derived glycodelin impairs in vitro dendritic cell maturation. J Immunother. 2009;32:492–497
  6. Nestle FO, Burg G, Fah J, Wrone-Smith T, Nickoloff BJ. Human sunlight-induced basal-cell-carcinoma-associated dendritic cells are deficient in T cell co-stimulatory molecules and are impaired as antigen-presenting cells. Am J Pathol. 1997;150:641–651
  7. Chaux P, Favre N, Martin M, Martin F. Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression in rats. Int J Cancer. 1997;72:619–624
  8. Curtin JP, Malik R, Venkatraman ES, Barakat RR, Hoskins WJ. Stage IV ovarian cancer: impact of surgical debulking. Gynecol Oncol. 1997;64:9–12
  9. Griffiths CT, Parker LM, Fuller AJ. Role of cytoreductive surgical treatment in the management of advanced ovarian cancer. Cancer Treat Rep. 1979;63:235–240
  10. National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat database: incidence—SEER 9 Regs Limited-Use, Nov 2008 Sub (1973–2006) <Katrina/Rita Population Adjustment>—linked to county attributes—Total U.S., 1969–2006 counties. Released April 2009, based on the November 2008 submission. [database on the Internet]. <http://www.seer.cancer.gov> Accessed September 2009.
  11. Diaz-Arias AA, Loy TS, Bickel JT, Chapman RK. Utility of BER-EP4 in the diagnosis of adenocarcinoma in effusions: an immunocytochemical study of 232 cases. Diagn Cytopathol. 1993;9:516–521
  12. Forster MD, Ormerod MG, Agarwal R, Kaye SB, Jackman AL. Flow cytometric method for determining folate receptor expression on ovarian carcinoma cells. Cytometry A. 2007;71A:945–950
  13. Bast RC, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981;68:1331–1337
  14. Canney PA, Moore M, Wilkinson PM, James RD. Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker. Br J Cancer. 1984;50:765–769
  15. Kabawat SE, Bast RC, Welch WR, Knapp RC, Colvin RB. Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid, and clear cell types. Am J Clin Pathol. 1983;79:98–104
  16. Meyer T, Rustin GJS. Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer. 2000;82:1535–1538
  17. Thaker PH, Deavers M, Celestino J, Thornton A, Fletcher MS, Landen CN, et al. EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res. 2004;10:5145–5150
  18. Han L, Dong Z, Qiao Y, Kristensen GB, Holm R, Nesland JM, et al. The clinical significance of EphA2 and Ephrin A-1 in epithelial ovarian carcinomas. Gynecol Oncol. 2005;99:278–286
  19. Harries M, Gore M. Part I: Chemotherapy for epithelial ovarian cancer—treatment at first diagnosis. Lancet Oncol. 2002;3:537–545
  20. Cohen LE. Cancer treatment and the ovary: the effects of chemotherapy and radiation. Ann NY Acad Sci. 2008;1135:123–125
  21. Scarberry KE, Dickerson EB, McDonald JF, Zhang ZJ. Magnetic nanoparticle-peptide conjugates for in vitro and in vivo targeting and extraction of cancer cells. J Am Chem Soc. 2008;130:10258–10262
  22. Liu C, Zou B, Rondinone AJ, Zhang ZJ. Chemical control of superparamagnetic properties of magnesium and cobalt spinel ferrite nanoparticles through atomic level magnetic couplings. J Am Chem Soc. 2000;122:6263–6267
  23. Clark KD, Volkman BF, Thoetkiattikul H, Hayakawa Y, Strand MR. N-terminal residues of plasmatocyte-spreading peptide possess specific determinants required for biological activity. J Biol Chem. 2001;276:37431–37435
  24. Ziselman EM, Harkavy SE, Hogan M, West W, Atkinson B. Peritoneal washing cytology. Uses and diagnostic criteria in gynecologic neoplasms. Acta Cytol. 1984;28:105–110
  25. Croonen AM, van der Valk P, Herman CJ, Lindeman J. Cytology, immunopathology and flow cytometry in the diagnosis of pleural and peritoneal effusions. Lab Invest. 1988;58:725–732
  26. Koolpe M, Dail M, Pasquale EB. An ephrin mimetic peptide that selectively targets the EphA2 receptor. J Biol Chem. 2002;277:46974–46979
  27. Shield PW, Callan JJ, Devine PL. Markers for metastatic adenocarcinoma in serous effusion specimens. Diagn Cytopathol. 1994;11:237–245
  28. Tuxen MK, Soletormos G, Dombernowsky P. Tumour markers in the management of patients with ovarian cancer. Cancer Treat Rev. 1995;21:215–245
  29. Hafner C, Schmitz G, Meyer S, Bataille F, Hau P, Langmann T, et al. Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers. Clin Chem. 2004;50:490–499
  30. Pasquale EB. The Eph family of receptors. Curr Opin Cell Biol. 1997;9:608–615
  31. Cheng N, Brantley DM, Chen J. The ephrins and Eph receptors in angiogenesis. Cytokine Growth Factor. 2002;13:75–85
  32. Barth MW, Morahan PS. Role of macrophages in the host response to Lewis lung peritoneal carcinomatosis. Cancer Immunol Immunother. 1994;38:233–242
  33. Zhou LJ, Tedder TF. Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily. J Immunol. 1995;154:3821–3835
  34. Tan D, Agarwal R, Kaye SB. Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol. 2006;7:925–934
  35. Hubbuch J, Matthiesen D, Hobley T, Thomas O. High-gradient magnetic separation versus expanded-bed absorption: a first principle comparison. Bioseparation. 2001;10:99–112

 The research was supported by grants from The Ovarian Cycle Foundation, The Deborah Nash Harris Endowment, and the Ovarian Cancer Institute.

PII: S1549-9634(09)00255-X

doi: 10.1016/j.nano.2009.11.003

Nanomedicine: Nanotechnology, Biology and Medicine
Volume 6, Issue 3 , Pages 399-408 , June 2010

Article Tools

* Image Usage & Resolution